Late Breaker: SAVR vs. TAVR in Low Risk Patients...What's the Data So Far?

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Thomas MacGillivray, MD

Elaine Tseng, MD
Disclosure(s): Amgen Inc.: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Artivion,: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Avania/Cellphire: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Portrero Med Inc: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, October 28, 2022)

Presentations

  1. Five Year Clinical and Echocardiographic Outcomes from the PARTNER 3 Low-Risk Randomized Trial
    Michael Mack, MD
    Disclosure(s): Carmat: Corporate Board Member (Ongoing); Edwards Lifesciences: Trial Co-PI (Ongoing); Medtronic: Study Chair (Ongoing)
     
  2. Four Year Outcomes from the EVOLUT Low Risk Trial
    Michael J. Reardon, MD
    Disclosure(s): AstraZeneca; Boston Scientific; Cook Medical; Ethicon; Merck & Co., Inc., Rahway, NJ, USA; Novartis; BMS: Consultant (Ongoing)
     
  3. Survival after SAVR in Low-Risk Patients: A Contemporary Trial Benchmark
    Vinay Badhwar, MD
     
  4. Late Breaking: Five Year Clinical and Echocardiographic Outcomes in Low-Risk Patients Undergoing Surgery in the PARTNER 3 Trial
    Vinod H. Thourani, MD
    Disclosure(s): Abbott Vascular: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Artivion: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); AtriCure: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Boston Scientific: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); dasi simulations: Advisory Board (Ongoing); Edwards Life Science: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Jenavalve: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Medtronic: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
     
  5. Panel Discussion and Audience Q&A
Activity summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 Participation
Activity opens: 
02/01/2024
Activity expires: 
02/15/2027
Cost:
$0.00
Rating: 
5

Available Credit

  • 1.50 AMA PRA Category 1 Credit
  • 1.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Thomas MacGillivray, MD

Elaine Tseng, MD
Disclosure(s): Amgen Inc.: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Artivion,: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Avania/Cellphire: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Portrero Med Inc: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, October 28, 2022)

Presentations

  1. Five Year Clinical and Echocardiographic Outcomes from the PARTNER 3 Low-Risk Randomized Trial
    Michael Mack, MD
    Disclosure(s): Carmat: Corporate Board Member (Ongoing); Edwards Lifesciences: Trial Co-PI (Ongoing); Medtronic: Study Chair (Ongoing)
     
  2. Four Year Outcomes from the EVOLUT Low Risk Trial
    Michael J. Reardon, MD
    Disclosure(s): AstraZeneca; Boston Scientific; Cook Medical; Ethicon; Merck & Co., Inc., Rahway, NJ, USA; Novartis; BMS: Consultant (Ongoing)
     
  3. Survival after SAVR in Low-Risk Patients: A Contemporary Trial Benchmark
    Vinay Badhwar, MD
     
  4. Late Breaking: Five Year Clinical and Echocardiographic Outcomes in Low-Risk Patients Undergoing Surgery in the PARTNER 3 Trial
    Vinod H. Thourani, MD
    Disclosure(s): Abbott Vascular: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Artivion: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); AtriCure: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Boston Scientific: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); dasi simulations: Advisory Board (Ongoing); Edwards Life Science: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Jenavalve: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Medtronic: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
     
  5. Panel Discussion and Audience Q&A